Mobia Medical set final terms this week for a $150 million initial public offering, marking the first pure-play nerve stimulation device manufacturer to test public markets since Boston Scientific's $615 million acquisition of Relievant Medsystems in late 2022. The company manufactures implantable devices targeting chronic pain through peripheral nerve modulation, a segment that has seen $2.7 billion in private capital deployed since 2020 but minimal IPO activity.
The IPO arrives as MedTech public offerings resume after an 18-month near-freeze. Two factors converged: the FDA accelerated 510(k) clearance timelines by an average of 43 days in Q4 2024, and the Russell 2000 Healthcare Equipment index climbed 18% since October, crossing the 1,850 threshold that historically correlates with successful sub-$200 million device offerings. Mobia's timing suggests confidence in reimbursement visibility—CMS finalized new CPT codes for neuromodulation procedures effective January 2025, covering 14 previously unbilled peripheral nerve targets. The company has not disclosed share price range, underwriter syndicate, or lock-up terms, which typically surface 48-72 hours before pricing.
Three elements merit attention. First, the $150 million raise positions Mobia in the narrow band where device companies have historically succeeded—large enough for institutional float, small enough to avoid direct comparison to Medtronic or Abbott. Second, nerve stimulation competes with both pharmaceutical pain management (a $28 billion U.S. market losing share to non-opioid alternatives) and surgical intervention (where device margins run 68-74% versus 52-58% for disposables). Mobia's technology sits at the intersection, suggesting a thesis around procedure substitution rather than pure market expansion. Third, the IPO tests appetite for single-indication device platforms. Recent filings show 83% of MedTech IPOs since 2019 failed when companies held fewer than three FDA-cleared products at debut. Mobia's product breadth remains undisclosed in preliminary filings.
Allocators should track three follow-on events. The full S-1 amendment—expected within 48 hours of this pricing—will reveal trailing twelve-month revenue, gross margin structure, and clinical trial endpoints that determine Medicare coverage breadth. Lock-up expirations typically occur 180 days post-IPO, with 72% of sub-$200 million MedTech offerings experiencing 15-30% drawdowns in the subsequent 45 days as early investors rotate. Finally, CMS will publish final 2026 reimbursement rates in November 2025, which historically move neuromodulation device stocks 8-12% on release day.
The IPO window for devices under $500 million enterprise value has been closed since March 2023, when Acclarent's withdrawn offering froze the pipeline. Mobia's pricing this week is the functional test case for whether that window remains shut or is now ajar.